Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications

Abivax SA ((GB:0RA9)) announced an update on their ongoing clinical study.

Abivax S.A. is conducting a Phase 2b clinical study titled A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn’s Disease. The study aims to assess the efficacy and safety of obefazimod as both an induction and maintenance therapy for patients with moderately to severely active Crohn’s Disease who have not responded adequately to conventional or advanced therapies.

The intervention being tested is Obefazimod, a drug administered once daily, with doses of 50mg, 25mg, and 12.5mg being compared to a placebo. The purpose of the drug is to provide a new treatment option for Crohn’s Disease, potentially offering improved outcomes for patients.

This study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. It involves quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all unaware of the treatment allocations. The primary purpose of the study is treatment-focused.

The study began on October 30, 2024, and is currently recruiting participants. The last update was submitted on August 11, 2025. These dates are crucial as they indicate the study’s progress and ongoing status, which is important for tracking potential market impacts.

The update on this clinical study could influence Abivax S.A.’s stock performance and investor sentiment, as successful results may position Obefazimod as a competitive treatment option in the Crohn’s Disease market. Investors should also consider the broader industry context, including existing treatments and competitors, when evaluating potential impacts.

The study is ongoing, with further details available on the ClinicalTrials portal.